Difference between revisions of "Team:SDU-Denmark/Tour20"
| Line 9: | Line 9: | ||
<span class="tooltip"> | <span class="tooltip"> | ||
<span class="tooltipHeader">Reference:</span> | <span class="tooltipHeader">Reference:</span> | ||
| − | Liu JK1. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. 2014 Sep 11;3(4):113-6. DOI: 10.1016/j.amsu.2014.09.001. | + | Liu JK1. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. 2014 Sep 11;3(4):113-6. <br>DOI: 10.1016/j.amsu.2014.09.001. |
<a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445/ "> (Link) </a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445/ "> (Link) </a> | ||
Revision as of 14:41, 10 September 2015
The antibody issue
As mentioned in the introduction, monoclonal antibodies (mAbs) are frequently used for numerous purposes in research and in medical aspects and the demand is continuously growing. The production market is exponentially rising. The current era of mAbs was initiated by the hybridoma technology developed by Kohler and Milstein in 1975.
Reference:
Liu JK1. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. 2014 Sep 11;3(4):113-6.
DOI: 10.1016/j.amsu.2014.09.001.
(Link)
In general it may cost between $4,000 - $30,000 to develop and produce monoclonal antibody in animals. Reference: Immunochemistry Technologies (Link) The mice are immunized often either intraperitonealt and/or subcutaenous with a certain antigen, throug a continuar